Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/94434
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Plasma n-3 fatty acids and clinical outcomes in recent-onset rheumatoid arthritis |
Author: | Proudman, S. Cleland, L. Metcalf, R. Sullivan, T. Spargo, L. James, M. |
Citation: | The British Journal of Nutrition: an international journal of nutritional science, 2015; 114(06):885-890 |
Publisher: | Cambridge University Press |
Issue Date: | 2015 |
ISSN: | 0007-1145 1475-2662 |
Statement of Responsibility: | Susanna M. Proudman, Leslie G. Cleland, Robert G. Metcalf, Thomas R. Sullivan, Llewellyn D. Spargo, and Michael J. James |
Abstract: | A randomised controlled trial (RCT) of high-dose v. low-dose fish oil in recent-onset rheumatoid arthritis (RA) demonstrated that the group allocated to high-dose fish oil had increased remission and decreased failure of disease-modifying anti-rheumatic drug (DMARD) therapy. This study examines the relationships between plasma phospholipid levels of the n-3 fatty acids in fish oil, EPA and DHA, and remission and DMARD use in recent-onset RA. EPA and DHA were measured in blood samples from both groups of the RCT. The data were analysed as a single cohort, and Cox proportional hazards models were used to examine relationships between plasma phospholipid (PL) EPA and DHA and various outcome measures. When analysed as a single cohort, plasma PL EPA was related to time to remission, with a one unit increase in EPA (1% total fatty acids) associated with a 12% increase in the probability of remission at any time during the study period (hazard ratio (HR)=1·12; 95% CI 1·02, 1·23; P=0·02). Adjustment for smoking, anti-cyclic citrullinated peptide antibodies and 'shared epitope' HLA-DR allele status did not change the HR. Plasma PL EPA, adjusted for the same variables, was negatively related to time to DMARD failure (HR=0·85; 95% CI 0·72, 0·99; P=0·047). The HR for DHA and time to remission or DMARD failure were similar in magnitude to those for EPA, but not statistically significant. Biomarkers of n-3 status, such as plasma PL EPA, have the potential to predict clinical outcomes relevant to standard drug treatment of RA patients. |
Keywords: | Fish oil; eicosapentaenoic acid; docosahexaenoic acid; arthritis; nutritional immunology |
Rights: | © The Authors 2015 |
DOI: | 10.1017/s0007114515002718 |
Published version: | http://dx.doi.org/10.1017/s0007114515002718 |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.